Background Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated
with encouraging overall survival in uncontrolled studies involving previously treated …

Background Patients with metastatic urothelial carcinoma have a dismal prognosis and few
treatment options after first-line chemotherapy. Responses to second-line treatment are …

Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …

INTRODUCTION Immunotherapy targeting the programmed cell death protein–1 (PD-1) axis
elicits durable antitumor responses in multiple cancer types. However, clinical responses …

Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …

Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely
variable clinical outcomes and responses to conventional chemotherapy. We discovered …

Background More than half of all patients with advanced urothelial cancer cannot receive
standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor …

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment,
and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune
checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the …